D. E. Shaw & Co., Inc. Protagonist Therapeutics, Inc Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 13,152 shares of PTGX stock, worth $583,554. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,152

Previous 35,640 63.1%

Holding current value

$583,554

Previous $1.03 Million 55.87%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $554,554 - $782,582	-22,488 Reduced 63.1%	13,152 $455,000
Q1 2024 May 15, 2024	BUY	$21.79 - $32.15 $776,595 - $1.15 Million	35,640 New	35,640 $1.03 Million
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $2.29 Million - $3.72 Million	-126,830 Reduced 63.57%	72,686 $2.01 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $123,754 - $291,362	11,480 Added 6.11%	199,516 $4.59 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $330,912 - $502,214	44,961 Added 31.42%	188,036 $2.05 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $1.12 Million - $1.68 Million	143,075 New	143,075 $1.21 Million
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $1.01 Million - $1.56 Million	-43,286 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $1.28 Million - $2.69 Million	-72,627 Reduced 62.66%	43,286 $1.48 Million
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $1.71 Million - $6.58 Million	-132,322 Reduced 53.31%	115,913 $2.05 Million
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $1.21 Million - $2.12 Million	47,255 Added 23.51%	248,235 $11.1 Million
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $2.58 Million - $4.23 Million	-135,876 Reduced 40.34%	200,980 $5.21 Million
Q4 2020 Feb 16, 2021	SELL	$18.49 - $25.13 $3.53 Million - $4.8 Million	-190,977 Reduced 36.18%	336,856 $6.79 Million
Q3 2020 Nov 16, 2020	SELL	$15.19 - $22.4 $4.33 Million - $6.39 Million	-285,113 Reduced 35.07%	527,833 $10.3 Million
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $3.3 Million - $10 Million	532,412 Added 189.79%	812,946 $14.4 Million
Q1 2020 May 15, 2020	SELL	$5.4 - $9.22 $809,908 - $1.38 Million	-149,983 Reduced 34.84%	280,534 $1.98 Million
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $470,632 - $1.35 Million	100,348 Added 30.39%	430,517 $3.04 Million
Q3 2019 Nov 14, 2019	SELL	$9.41 - $16.56 $631,495 - $1.11 Million	-67,109 Reduced 16.89%	330,169 $3.97 Million
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $1.25 Million - $1.81 Million	139,550 Added 54.15%	397,278 $4.81 Million
Q1 2019 May 15, 2019	BUY	$6.5 - $13.77 $1.55 Million - $3.28 Million	238,083 Added 1211.93%	257,728 $3.24 Million
Q4 2018 Feb 14, 2019	BUY	$6.3 - $10.44 $53,235 - $88,218	8,450 Added 75.48%	19,645 $132,000
Q3 2018 Nov 14, 2018	SELL	$6.82 - $11.26 $266,430 - $439,883	-39,066 Reduced 77.73%	11,195 $115,000
Q2 2018 Aug 14, 2018	BUY	$5.99 - $9.1 $301,063 - $457,375	50,261 New	50,261 $337,000
Q1 2018 May 15, 2018	SELL	$8.46 - $23.08 $264,383 - $721,273	-31,251 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $452,201 - $650,020	31,251	31,251 $650,000

Others Institutions Holding PTGX

# of Institutions

196

Shares Held

58.7M

Call Options Held

20.8K

Put Options Held

109K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.18B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account